Table 3.
miRNA | Expression in CSCs | Relation to Stemness | Reference |
---|---|---|---|
miR-26a | Downregulated | Targets HOXC9 | [89] |
Overexpression reduces self-renewal capacity of spheroid cells and invasive capacity | |||
miR-106b | Upregulated | Upregulated in CD44+ cells | [87] |
Targets SMAD7 | |||
miR-193-3p | Upregulated | Overexpression increases resistance to 5-FU and cisplatin1 | [90] |
miR-196a-5p | Upregulated | Upregulated in CD44+ cells | [88] |
Targets SMAD4 | |||
miR-200a | Downregulated | Downregulated in ZEB1+ and Snail+, invasive cells | [91] |
miR-200c | N/A | Delivery with micelle-based nanoparticles enhances sensitivity to radiotherapy 1 | [92] |
miR-216a-3p | Downregulated | Downregulated by BRD4 | [93] |
Targets Wnt3a | |||
miR-524-5p | Downregulated | Enhances sensitivity to cisplatin 1 | [94] |
miR-876-3p | Downregulated | Enhances sensitivity to cisplatin 1 | [95] |
Targets SMAD4 |
1 These miRNAs have demonstrated therapeutic potential.